• Profile
Close

Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: The CARMELINA randomized clinical trial

JAMA Nov 14, 2018

Rosenstock J, et al. - In patients with type 2 diabetes at high risk of cardiovascular (CV) and kidney events, investigators assessed the impact of linagliptin—a selective dipeptidyl peptidase 4 (DPP-4) inhibitor— on CV and kidney outcomes. A noninferior risk of a composite CV outcome over a median 2.2 years resulted with linagliptin added to usual care vs placebo added to usual care in this study population.

Methods

  • Experts conducted this randomized, placebo-controlled, multicenter noninferiority trial from August 2013 to August 2016 at 605 clinic sites in 27 countries among adults with type 2 diabetes and a hemoglobin A1c of 6.5% to 10.0%, high CV risk, and high renal risk.
  • They excluded those with end-stage renal disease (ESRD).
  • Final follow-up occurred on January 18, 2018.
  • They randomized the patients to receive linagliptin 5 mg once daily (n=3,494) or placebo once daily (n=3,485) added to usual care.
  • Based on clinical need and local clinical guidelines, other glucose-lowering medications or insulin could be added.
  • Time to first occurrence of the composite of CV death, nonfatal myocardial infarction, or nonfatal stroke was the primary outcome.
  • They defined the criteria for noninferiority of linagliptin vs placebo by the upper limit of the 2-sided 95% CI for the HR of linagliptin relative to placebo being < 1.3.
  • Time to first occurrence of adjudicated death due to renal failure, ESRD, or sustained ≥ 40% decrease in eGFR from baseline were included in the secondary outcome.

Results

  • Of 6,991 enrollees, ≥ 1 dose of study medication was received by 6,979, and 98.7% completed the study.
  • The primary outcome, during a median follow-up of 2.2 years, occurred in 12.4% and 12.1% in the linagliptin and placebo groups, respectively.
  • Findings suggested the occurrence of kidney outcome in 9.4% and 8.8%, respectively.
  • In 2,697 (77.2%) and 2,723 (78.1%) patients in the linagliptin and placebo groups, adverse events occurred; ≥ 1 episodes of hypoglycemia were observed in 1,036 (29.7%) and 1,024 (29.4%) patients; and there were 9 (0.3%) vs 5 (0.1%) events of adjudication-confirmed acute pancreatitis.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay